Balancing N-linked glycosylation to avoid disease

Biochimie

Volumn 83, Issue 8, 2001, Pages 791-799

  Freeze, H H ^a   Westphal, V ^a  

^a BURNHAM INSTITUTE   (United States)

Author keywords

Congenital disorder(s) of glycosylation; Hepatitis; Mental retardation; Single nucleotide polymorphism; Viral infection

Indexed keywords

1 DEOXYNOJIRIMYCIN; 1 DEOXYNOJIRIMYCIN DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; GLYCOSYLTRANSFERASE; PHOSPHOMANNOMUTASE; TUNICAMYCIN;

ALLELE; BIOSYNTHESIS; CLINICAL TRIAL; DRUG EFFECT; DRUG INHIBITION; ENTEROPATHY; GENE MUTATION; GENETIC CODE; GENETIC DISORDER; GLYCOSYLATION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HETEROSIS; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; LETHAL GENE; LIVER DYSFUNCTION; MENTAL DEFICIENCY; MULTIGENE FAMILY; PATHOLOGY; PREVALENCE; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; VIRUS INFECTION;

HEPATITIS VIRUS B; MAMMALIA;

EID: 0034838701     PISSN: 03009084     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-9084(01)01292-5     Document Type: Article

References (89)

1. Congenital disorders of glycosylation: Glycosylation defects in man and biological models for their study
2. Congenital disorders of glycosylation: Genetic model systems lead the way
3. Carbohydrate-deficient glycoprotein syndrome become congenital disorders of glycosylation: An updated nomenclature for CDG
4. Mutations in PMM2 that cause congenital disorders of glycosylation, type Ia (CDG-Ia)
5. Congenital disorders of glycosylation: Have you encountered them?
6. Synergistic heterozygosity: Disease resulting from multiple partial defects in one or more metabolic pathways
7. The frequency and origin of the sickle cell mutation in the district of Coruche/Portugal
8. Selective advantage of the sickle-cell trait
9. Hypothesis: A selective advantage for cystic fibrosis heterozygotes
10. A selective advantage for cystic fibrosis carriers
11. Cystic fibrosis heterozygote resistance to cholera toxin in the cystic fibrosis mouse model
12. The dolichol pathway of N-linked glycosylation
13. Protein translocation into the endoplasmic reticulum (ER) - Two similar routes with different modes
14. Transport of proteins across the endoplasmic reticulum membrane
15. Protein glycosylation in yeast
16. Assembly of asparagine-linked oligosaccharides
17. The quality control of glycoprotein folding in the endoplasmic reticulum, a trip from trypanosomes to mammals
18. Quality control in the secretory pathway
19. Setting the standards: Quality control in the secretory pathway
20. Evidence that N-linked glycosylation is necessary for hepatitis B virus secretion
21. On the frequency of protein glycosylation, as deduced from analysis of the SWISS-PROT database
22. Glycosylation efficiency of Asn-Xaa-Thr sequons depends both on the distance from the C terminus and on the presence of a downstream transmembrane segment
23. Regulation of N-linked core glycosylation: Use of a site-directed mutagenesis approach to identify Asn-Xaa-Ser/Thr sequons that are poor oligosaccharide acceptors
24. The hydroxy amino acid in an Asn-X-Ser/Thr sequon can influence N-linked core glycosylation efficiency and the level of expression of a cell surface glycoprotein
25. The amino acid at the X position of an Asn-X-Ser sequon is an important determinant of N-linked core-glycosylation efficiency
26. Sequence differences between glycosylated and non-glycosylated Asn-X-Thr/Ser acceptor sites: Implications for protein engineering
27. Biological roles of oligosaccharides: All of the theories are correct
28. Expression of dolichol-linked saccharide intermediate synthesis during the development of B lymphocytes
29. Mutants in dolichol synthesis: Conversion of polyprenol to dolichol appears to be a rate-limiting step in dolichol synthesis
30. Synthesis of lipid-linked oligosaccharides is dependent on the cell cycle in rat 3Y1 cells
31. Effect of ethanol administration on the level of dolichol in rat liver microsomes and Golgi apparatus
32. Long-term ethanol exposure impairs glycosylation of both N- and O-glycosylated proteins in rat liver
33. Carbohydrate composition of serum transferrin isoforms from patients with high alcohol consumption
34. Possible reasons why heavy drinking increases carbohydrate-deficient transferrin
35. Carbohydrate-deficient transferrin in healthy women: Relation to estrogens and iron status
36. Increased carbohydrate-deficient transferrin during pregnancy: Relation to sex hormones
37. Catabolic pathway of oligosaccharide-diphospho-dolichol. Subcellular sites of the degradation of the oligomannoside moiety
38. 'Glyco-deglyco' processes during the synthesis of N-glycoproteins
39. Transport of free and N-linked oligomannoside species across the rough endoplasmic reticulum membranes
40. Trafficking of oligomannosides released during N-glycosylation: A clearing mechanism of the rough endoplasmic reticulum
41. Intracellular functions of N-linked glycans
42. An additional carbohydrate chain in the variant thyroxine-binding globulin-Gary (TBGAsn-96) impairs its secretion
43. Translation rate of human tyrosinase determines its N-linked glycosylation level
44. Truncated profibrillin of a Marfan patient is of apparent similar size as fibrillin: Intracellular retention leads to over-N-glycosylation
45. A point mutation creating an extra N-glycosylation site in fibrillin-1 results in neonatal Marfan syndrome
46. Clinical, pathological and molecular genetic findings in a case of neonatal Marfan syndrome
47. Regulation of fibrillin carboxy-terminal furin processing by N-glycosylation, and association of amino- and carboxy-terminal sequences
48. The nature and metabolism of the carbohydrate-peptide linkages of glycoproteins
49. Proteolysis of a neuronal glutamate receptor generates an autoantigen and is modulated by glycosylation
50. Autoantibodies to glutamate receptor GluR3 in Rasmussen's encephalitis
51. Defective glycosyltransferases are not good for your health
52. Carbohydrate-deficient glycoprotein syndrome
53. The carbohydrate-deficient glycoprotein syndrome. A new inherited multisystemic disease with severe nervous system involvement
54. Direct utilization of mannose for mammalian glycoprotein biosynthesis
55. Mannose supplementation corrects GDP-mannose deficiency in cultured fibroblasts from some patients with congenital disorders of glycosylation (CDG)
56. Failure of short-term mannose therapy of patients with carbohydrate-deficient glycoprotein syndrome type 1A
57. Mannose corrects altered N-glycosylation in carbohydrate-deficient glycoprotein syndrome fibroblasts
58. High residual activity of PMM2 in patients' fibroblasts: Possible pitfall in the diagnosis of CDG-Ia (phosphomannomutase deficiency)
59. Carbohydrate-deficient glycoprotein syndrome type Ib. Phosphomannose isomerase deficiency and mannose therapy
60. Human glycosylation disorders and sugar supplement therapy
61. A mutation in the human ortholog of the Saccharomyces cerevisiae ALG6 gene causes carbohydrate-deficient glycoprotein syndrome type-Ic
62. Carbohydrate-deficient glycoprotein syndrome type V: Deficiency of dolichyl-P-Glc:Man9GlcNAc2-PP-dolichyl glucosyltransferase
63. Carbohydrate deficient glycoprotein syndrome type IV: Deficiency of dolichyl-P-Man:Man(5)GlcNAc(2)-PP-dolichyl mannosyltransferase
64. Dolichol phosphate mannose synthase (DPM1) mutations define congenital disorder of glycosylation Ie (CDG-Ie)
65. Deficiency of dolichol-phosphate-mannose synthase-1 causes congenital disorder of glycosylation type Ie
66. Clinical and biochemical characteristics of congenital disorder of glycosylation type Ic, the first recognized endoplasmic reticulum defect in N-glycan synthesis
67. Requirement of the lec35 gene for all known classes of monosaccharide-p-dolichol-dependent glycosyltransferase reactions in mammals
68. The yeast WBP1 is essential for oligosaccharyl transferase activity in vivo and in vitro
69. Stepwise assembly of the lipid-linked oligosaccharide in the endoplasmic reticulum of Saccharomyces cerevisiae: Identification of the ALG9 gene encoding a putative mannosyl transferase
70. Multi-allelic origin of congenital disorder of glycosylation (CDG)-Ic
71. Reduced heparan sulfate accumulation in enterocytes contributes to protein-losing enteropathy in a congenital disorder of glycosylation
72. Analysis of multiple mutations in the hALG6 gene in a patient with congenital disorder of glycosylation Ic
73. Molecular heterosis: A review
74. Why are some genetic diseases common? Distinguishing selection from other processes by molecular analysis of globin gene variants
75. A strategy for anti-viral intervention: The use of alpha-glucosidase inhibitors to prevent chaperone-mediated folding of viral envelope glycoproteins
76. Hepatitis B virus (HBV) envelope glycoproteins vary drastically in their sensitivity to glycan processing: Evidence that alteration of a single N-linked glycosylation site can regulate HBV secretion
77. The role of N-linked glycosylation in the secretion of hepatitis B virus
78. Glycosylation and the immune system
79. Searching for medicine's sweet spot
80. Imino sugars inhibit the formation and secretion of bovine viral diarrhea virus, a pestivirus model of hepatitis C virus: Implications for the development of broad spectrum anti-hepatitis virus agents
81. Epidemiology, prevention and treatment of viral hepatitis with emphasis on new developments
82. Alpha-glucosidase inhibitors as potential broad based anti-viral agents
83. Expression of rabies virus glycoprotein from a recombinant vaccinia virus
84. The ascension of wildlife rabies: A cause for public health concern or intervention?
85. Folding of rabies virus glycoprotein: Epitope acquisition and interaction with endoplasmic reticulum chaperones
86. N-linked glycosylation of rabies virus glycoprotein. Individual sequons differ in their glycosylation efficiencies and influence on cell surface expression
87. The relative power of SNPs and haplotype as genetic markers for association tests
88. Association study designs for complex diseases